A Blueprint for Breakthrough – Charting the Course for Precision Medicine

A Blueprint for Breakthrough – Charting the Course for Precision Medicine

September 13, 2017
Marriott Marquis Hotel

 901 Massachusetts Ave NW, Washington, DC 20001


Thank you to all that attended. To access a full recap, including links to relevant papers, videos, and presentations, Click HERE.


Join us on September 13, 2017, as Friends of Cancer Research and Alexandria Real Estate Equities Inc. host this year’s Blueprint for Breakthroughs. This year’s event will focus on the course ahead for precision medicine and will include a morning keynote address and two panel discussions.


Please find this year’s agenda below.

8:00 AM - Registration and Breakfast

8:30 AM - Welcome Remarks

  • Ellen Sigal, Friends of Cancer Research
  • Lynne Zydowsky, Alexandria Real Estate Equities, Inc.

8:40 AM - Morning Keynote Address

  • Scott Gottlieb, Commissioner, U.S. FDA

9:00AM - Regulatory Landscape for Precision Medicine

  • Adam Berger, U.S. FDA

9:15AM - Current State of Precision Medicine Development

  • Julie Dixon, Bristol-Myers Squibb

Panel 1 Discussion: Establishing Analytical Standards and Identifying Critical Performance Characteristics

Moderator: Mya Thomae, Regulatory Advisor

  • Dara Aisner, University of Colorado Denver
  • Rasika Kalamegham, Genentech
  • Lisa McShane, NCI
  • Jason Merker, Stanford University
  • Reena Philip, U.S. FDA
  • Erasmus Schneider, NY State Department of Health

Panel 2 Discussion: Streamlining Modifications to Diagnostic Tests

Moderator: Elizabeth Mansfield, GRAIL

  • Gideon Blumenthal, U.S. FDA
  • Keith Flaherty, Massachusetts General Hospital
  • David Kaufman, Merck
  • David Litwack, U.S. FDA
  • Kelli Tanzella, Thermo Fisher Scientific

Panel 3 Discussion: Driving Uptake of High Quality Precision Medicine Tools

Moderator: Kate Rawson, Prevision Policy

  • Joseph Chin, CMS
  • Andrea Ferris, Lungevity
  • Zach Hornby, Ignyta
  • John Iafrate, Massachusetts General Hospital
  • Michael Pellini, Foundation Medicine
  • Jeffrey Shuren, U.S. FDA